Skip to main content

Advertisement

SpringerLink
Log in

Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy

  • Sleep (M. Thorpy, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Narcolepsy is a central disorder of hypersomnolence with symptoms of excessive daytime sleepiness, sleep paralysis, and cataplexy. Cataplexy is the sudden loss of muscle tone in either the face, neck, trunk, and/or limbs, leading to a loss of voluntary muscle control. This article reviews recent research on the clinical characteristics of cataplexy.

Recent Findings

Longitudinal research in adults suggests that there may be a remission of cataplectic severity after symptom stabilization. First-line treatment options for cataplexy include sodium oxybate and pitolisant, with many drugs such as AXS-12, FT218, and JZP258 under investigation. Patients with cataplexy reported greater limitations of daily activities such as driving and exercise compared to patients without cataplexy.

Summary

Cataplexy remains a challenge for children and adults with narcolepsy and can interfere with daily activities. There is no cure for narcolepsy, but cataplexy can be well-managed with current and promising new treatment options on the horizon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. AASM. The American Academy of Sleep Medicine-International Classification of Sleep Disorders, Diagnostic and Coding Manual. 3 ed2014.

  2. Viorritto EN, Kureshi SA, Owens JA. Narcolepsy in the pediatric population. Curr Neurol Neurosci Rep. 2012;12(2):175–81.

    CAS  PubMed  Google Scholar 

  3. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–62.

    CAS  PubMed  Google Scholar 

  4. Nevsimalova S. The diagnosis and treatment of pediatric narcolepsy. Cur Neurol Neurosci Rep. 2014;14(8):469.

    Google Scholar 

  5. Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955–65.

    PubMed  PubMed Central  Google Scholar 

  6. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology. 1993;43(1):55–60.

    CAS  PubMed  Google Scholar 

  7. Huang B, Xu T, Wang Z, Chen K, Zhang J, Zhao Z, et al. The clinical characteristics of cataplectic attack in narcolepsy type 1. Sleep Med. 2019.

  8. Plazzi G, Clawges HM, Owens JA. Clinical characteristics and burden of illness in pediatric patients with narcolepsy. Pediatr Neurol. 2018;85:21–32.

    PubMed  Google Scholar 

  9. Dhanju S, Al-Saleh S, Amin R, et al. A retrospective analysis of clinical characteristics of childhood narcolepsy. Paediatr Child Health. 2018;23(6):e95–e101.

    PubMed  PubMed Central  Google Scholar 

  10. Dinkelacker V, Nguyen-Michel VH, Thivard L, Navarro V, Adam C, Pallanca O, et al. "I feel my arm shaking": partial cataplexy mistaken for drug-resistant focal epilepsy. Sleep Med. 2017;36:119–21.

    PubMed  Google Scholar 

  11. Antelmi E, Pizza F, Vandi S, Plazzi G. Stereotyped episodes of aphasia and immobility: how cataplexy mimics stroke in an elderly patient. Sleep Med. 2017;36:122–4.

    CAS  PubMed  Google Scholar 

  12. Meinen CN, Smith KM, Tillema JM, Kotagal S. Pseudo status Cataplecticus in narcolepsy type 1. J Clin Sleep Med. 2018;14(9):1625–7.

    PubMed  PubMed Central  Google Scholar 

  13. Tio E, Gaig C, Giner-Soriano M, et al. The prevalence of narcolepsy in Catalunya (Spain). J Sleep Res. 2018;27(5):e12640.

    PubMed  Google Scholar 

  14. Pizza F, Vandi S, Liguori R, Parchi P, Avoni P, Mignot E, et al. Primary progressive narcolepsy type 1: the other side of the coin. Neurology. 2014;83(23):2189–90.

    PubMed  PubMed Central  Google Scholar 

  15. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Moore RY, Abrahamson EA, Van Den Pol A. The hypocretin neuron system: an arousal system in the human brain. Arch Ital Biol. 2001;139(3):195–205.

    CAS  PubMed  Google Scholar 

  17. Maski K, Owens JA. Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. Lancet Neurol. 2016;15(11):1170–81.

    PubMed  Google Scholar 

  18. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci. 2000;20(20):7760–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Picchioni D, Hope CR, Harsh JR. A case-control study of the environmental risk factors for narcolepsy. Neuroepidemiology. 2007;29(3–4):185–92.

    PubMed  Google Scholar 

  20. Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14(3):318–28.

    CAS  PubMed  Google Scholar 

  21. Luppi PH, Clement O, Sapin E, et al. The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med Rev. 2011;15(3):153–63.

    PubMed  Google Scholar 

  22. Hong SB, Tae WS, Joo EY. Cerebral perfusion changes during cataplexy in narcolepsy patients. Neurology. 2006;66(11):1747–9.

    PubMed  Google Scholar 

  23. • Torontali ZA, Fraigne JJ, Sanghera P, Horner R, Peever J. The sublaterodorsal tegmental nucleus functions to couple brain state and motor activity during REM sleep and wakefulness. Curr Biol. 2019;29(22):3803–3813.e3805 This study shows that the sublaterodorsal tegmental nucleus in the brain plays an important role in cataplexy physiology.

    CAS  PubMed  Google Scholar 

  24. Burgess CR, Oishi Y, Mochizuki T, Peever JH, Scammell TE. Amygdala lesions reduce cataplexy in orexin knock-out mice. J Neurosci. 2013;33(23):9734–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Peever J. Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy. Arch Ital Biol. 2011;149(4):454–66.

    CAS  PubMed  Google Scholar 

  26. Siegel JM, Nienhuis R, Fahringer HM, Paul R, Shiromani P, Dement W, et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science. 1991;252(5010):1315–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Kodama T, Lai YY, Siegel JM. Changes in inhibitory amino acid release linked to pontine-induced atonia: an in vivo microdialysis study. J Neurosci. 2003;23(4):1548–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. LeDoux J. The amygdala. Curr Biol. 2007;17(20):R868–74.

    CAS  PubMed  Google Scholar 

  29. Covington HE 3rd, Lobo MK, Maze I, et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci. 2010;30(48):16082–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Bassetti C, Aldrich MS. Narcolepsy. Neurol Clin. 1996;14(3):545–71.

    CAS  PubMed  Google Scholar 

  31. Morse AM. Narcolepsy in children and adults: a guide to improved recognition, diagnosis and management. Med Sci (Basel). 2019;7(12):106.

    Google Scholar 

  32. Buchele F, Baumann CR, Poryazova R, Werth E, Valko PO. Remitting narcolepsy? Longitudinal observations in a hypocretin-deficient cohort. Sleep. 2018;41(9).

  33. Almeneessier AS, Alballa NS, Alsalman BH, Aleissi S, Olaish AH, BaHammam AS. A 10-year longitudinal observational study of cataplexy in a cohort of narcolepsy type 1 patients. Nature Sci Sleep. 2019;11:231–9.

    Google Scholar 

  34. Franceschini C, Fante C, Folli MC, Filosa M, Pizza F, Antelmi E, et al. Giving a voice to Cataplectic experience: recalls from patients with narcolepsy type 1. J Clin Sleep Med. 2020;16:597–603.

    PubMed  PubMed Central  Google Scholar 

  35. Overeem S, Lammers GJ, van Dijk JG. Weak with laughter. In: Lancet. Vol 354. England1999:838.

  36. Barateau L, Pizza F, Lopez R, Antelmi E, Plazzi G, Dauvilliers Y. Persistence of deep-tendon reflexes during partial cataplexy. Sleep Med. 2018;45:80–2.

    PubMed  Google Scholar 

  37. Pizza F, Antelmi E, Vandi S, et al. The distinguishing motor features of cataplexy: a study from video-recorded attacks. Sleep. 2018;41(5).

  38. Huang B, Qian Z, Wang Z, Zhang J, Chen K, Xu T, et al. Fluctuation of primary motor cortex excitability during cataplexy in narcolepsy. Ann Clin Transl Neurol. 2019;6(2):210–21.

    PubMed  PubMed Central  Google Scholar 

  39. Chang ET, Lin CL, Chen SF, Shen YC. Risk of burn injury in patients with narcolepsy: a nationwide population-based cohort study. J Burn Care Res. 2020;41:663–7.

    PubMed  Google Scholar 

  40. Plazzi G, Pizza F, Palaia V, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain. 2011;134(Pt 12):3477–89.

    PubMed  PubMed Central  Google Scholar 

  41. Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord. 2008;23(6):858–65.

    PubMed  Google Scholar 

  42. Luca G, Haba-Rubio J, Dauvilliers Y, Lammers GJ, Overeem S, Donjacour CE, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European narcolepsy network study. J Sleep Res. 2013;22(5):482–95.

    PubMed  Google Scholar 

  43. Swick TJ. Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep. 2015;7:159–69.

    PubMed  PubMed Central  Google Scholar 

  44. Pizza F, Franceschini C, Peltola H, Vandi S, Finotti E, Ingravallo F, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136(Pt 12):3787–95.

    PubMed  PubMed Central  Google Scholar 

  45. Prasad M, Setty G, Ponnusamy A, Hussain N, Desurkar A. Cataplectic facies: clinical marker in the diagnosis of childhood narcolepsy-report of two cases. Pediatr Neurol. 2014;50(5):515–7.

    PubMed  Google Scholar 

  46. Maski K, Steinhart E, Williams D, Scammell T, Flygare J, McCleary K, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13(3):419–25.

    PubMed  PubMed Central  Google Scholar 

  47. Parmar A, Yeh EA, Korczak DJ, et al. Depressive symptoms, sleep patterns, and physical activity in adolescents with narcolepsy. Sleep. 2019;42(8).

  48. Stores G, Montgomery P, Wiggs L. The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics. 2006;118(4):e1116–23.

    PubMed  Google Scholar 

  49. Morse AM, Sanjeev K. Narcolepsy and Psychiatric Disorders: Comorbidities or Shared Pathophysiology? Med Sci (Basel). 2018;6(1).

  50. Ong JC, Fox RS, Brower RF, Mazurek S, Moore C. How does narcolepsy impact health-related quality of life? A mixed-methods study. Behav Sleep Med. 2020:1–14.

  51. Wehrle R, Bruck D. Growing up with narcolepsy. Somnologie - Schlafforschung und Schlafmedizin. 2011;15(1):32–8.

    Google Scholar 

  52. Inocente CO, Gustin MP, Lavault S, Guignard-Perret A, Raoux A, Christol N, et al. Depressive feelings in children with narcolepsy. Sleep Med. 2014;15(3):309–14.

    PubMed  Google Scholar 

  53. Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017;18(8):809–17.

    CAS  PubMed  Google Scholar 

  54. Bogan RK, Roth T, Schwartz J, Miloslavsky M. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015;11(4):427–32.

    PubMed  PubMed Central  Google Scholar 

  55. Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31(2):371–81.

    PubMed  Google Scholar 

  56. Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9–18.

    PubMed  Google Scholar 

  57. Drakatos P, Lykouras D, D'Ancona G, Higgins S, Gildeh N, Macavei R, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80–4.

    PubMed  PubMed Central  Google Scholar 

  58. Filardi M, Pizza F, Antelmi E, Ferri R, Natale V, Plazzi G. In-field assessment of sodium Oxybate effect in pediatric type 1 narcolepsy: an Actigraphic study. Sleep. 2018;41.

  59. Plazzi G, Ruoff C, Lecendreux M, et al. A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of sodium oxybate in pediatric subjects with narcolepsy with cataplexy. Sleep Med. 2017;40(suppl_1):e263.

    Google Scholar 

  60. Peacock J, Benca RM. Narcolepsy: clinical features, co-morbidities & treatment. Indian J Med Res. 2010;131:338–49.

    PubMed  Google Scholar 

  61. Calik MW. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nature Sci Sleep. 2017;9:127–33.

    Google Scholar 

  62. Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:1756286419875622.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Design Develop Ther. 2018;12:2665–75.

    CAS  Google Scholar 

  64. Syed YY. Pitolisant: first global approval. Drugs. 2016;76(13):1313–8.

    CAS  PubMed  Google Scholar 

  65. •• Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep. 2019;42(11) This study shows that Pitosilant treatment is effective in decreasing the daily number of generalized cataplexy episodes in adults with narcolepsy.

  66. Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41(12).

  67. Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55–60.

    CAS  PubMed  Google Scholar 

  68. Jin L, Shi L, Zhang Y, Chen BB, Wang XL, Liu YH. Antidepressants for the treatment of narcolepsy: a prospective study of 148 patients in northern China. J Clin Neurosci. 2019;63:27–31.

    CAS  PubMed  Google Scholar 

  69. Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519–39.

    PubMed  Google Scholar 

  70. Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–11.

    PubMed  PubMed Central  Google Scholar 

  71. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety. 2001;14(1):19–28.

    CAS  PubMed  Google Scholar 

  72. Moller LR, Ostergaard JR. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol. 2009;19(2):197–201.

    PubMed  Google Scholar 

  73. Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VCD, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14(1):30–6.

    PubMed  Google Scholar 

  74. Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020;68:97–109.

    PubMed  Google Scholar 

  75. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132(4):1027–34.

    CAS  PubMed  Google Scholar 

  76. Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nature Sci Sleep. 2017;9:39–57.

    Google Scholar 

  77. Fullam S, Scott A, Garvey JF. Status Cataplecticus following abrupt withdrawal of clomipramine. Ir Med J. 2019;112(8):991.

    CAS  PubMed  Google Scholar 

  78. Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51–61.

    PubMed  PubMed Central  Google Scholar 

  79. Shneerson JM, Dauvilliers YA, Plazzi G, Myers AJ, Garcia-Borreguero D. The impact of narcolepsy and its treatment-a European study. Eur Neurologic Rev. 2008;3(2):105–8.

    Google Scholar 

  80. Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9–27.

    PubMed  PubMed Central  Google Scholar 

  81. Jazz Pharmaceuticals announces positive top-line results from phase 3 study of JZP-258 in adult narcolepsy patients with cataplexy and excessive daytime sleepiness [press release]. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-positive-top-line-results-phase-3. Published 2019. Accessed April 25 2020.

  82. Bogan R, Thorpy M, Dauvilliers Y, Del Rio VR, Foldvary-Schaefer N, Skowronski R. Efficacy and safety of JZP-258 in a phase 3 double-blind, placebo-controlled, randomised-withdrawl study in adults with narcolepsy with cataplexy [abstract]. Biennial world sleep congress; 2019; Vancouver. Canada. .

  83. Avadel Pharmaceuticals receives orphan drug designation from FDA for FT 218 for the treatment of narcolepsy [press release]. http://investors.avadel.com/news-releases/news-releasedetails/avadel-pharmaceuticals-receives-orphan-drug-designation-fda-ft?ID=2325927&c=67519&p=irol-newsArticle. Published 2018. Accessed April 25 2020.

  84. Sodium oxybate controlled release—Avadel Pharmaceuticals [drug profle]. In:2018.

  85. Monteith D, Grassot J, Castellan C, Dubow J, Roth T. Pharmacokinetics and formulation selection of FT218 an investigational controlled-release sodium oxybate formulation designed for once-nightly dosing.

  86. Monteith D, Grassot J, Castellan C, Roth T. Pharmacokinetics and dose proportionality of FT218, an investigational controlled release formulation of sodium oxybate for once nightly dosing. 2019.

    Google Scholar 

  87. Axsome announces AXS-12 for narcolepsy [press release]. https://axsometherapeuticsinc.gcs-web.com/static-files/fa862bca-7be0-4849-9f00-68894655ab86. Published 2018. Accessed April 28 2020.

  88. Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24(3):282–5.

    CAS  PubMed  Google Scholar 

  89. Yukitake H, Fujimoto T, Ishikawa T, Suzuki A, Shimizu Y, Rikimaru K, et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacol Biochem Behav. 2019;187:172794.

    CAS  PubMed  Google Scholar 

  90. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin a) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26(8):953–9.

    PubMed  Google Scholar 

  91. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004;101(13):4649–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, et al. Effects of intranasal hypocretin-1 (orexin a) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941–6.

    CAS  PubMed  Google Scholar 

  93. Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Goder R, Baier PC. The effect of intranasal orexin-a (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8–13.

    CAS  PubMed  Google Scholar 

  94. Fam DJ, Shammi P, Mainprize TG, Murray BJ. Dramatic cataplexy improvement following right parietal surgery. J Clin Sleep Med. 2015;11(7):829–30.

    PubMed  PubMed Central  Google Scholar 

  95. Lim AS, Moro E, Lozano AM, Hamani C, Dostrovsky JO, Hutchison WD, et al. Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. Ann Neurol. 2009;66(1):110–4.

    PubMed  Google Scholar 

  96. Postiglione E, Antelmi E, Pizza F, Lecendreux M, Dauvilliers Y, Plazzi G. The clinical spectrum of childhood narcolepsy. Sleep Med Rev. 2018;38:70–85.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada

    Arpita Parmar

  2. Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Brian J. Murray

  3. Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Ave, Hill Wing-Room 4534, Toronto, ON, M5G 1X8, Canada

    Indra Narang

  4. University of Toronto, Toronto, ON, Canada

    Brian J. Murray & Indra Narang

Authors
  1. Arpita Parmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian J. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Indra Narang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Indra Narang.

Ethics declarations

Conflict of Interest

Arpita Parmar has no relevant disclosures.

Dr. Murray has no relevant disclosures.

Dr. Narang has no relevant disclosures.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Topical Collection on Sleep

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parmar, A., Murray, B.J. & Narang, I. Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy. Curr Neurol Neurosci Rep 20, 38 (2020). https://doi.org/10.1007/s11910-020-01057-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-020-01057-z

Keywords

Search

Navigation